NSE:ASTRAZEN (India)
Â
Shs Dematerialised
₹
8,058
-333 (-3.97%)
Jun 29
Business Description
AstraZeneca Pharma India Ltd
ISIN : INE203A01020
Share Class Description:
NSE:ASTRAZEN: Shs DematerialisedTotal Employee Number:
802Compare
Compare
Traded in other countries / regions
506820.India Index Membership
NIFTY 500 IPO Date
2001-05-04Description
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.13 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 0.39 | |||||
Interest Coverage | 51.99 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 13.29 | |||||
Beneish M-Score | -1.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.4 | |||||
3-Year EBITDA Growth Rate | 23.6 | |||||
3-Year EPS without NRI Growth Rate | 14.6 | |||||
3-Year Book Growth Rate | 14 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.14 | |||||
9-Day RSI | 29.19 | |||||
14-Day RSI | 35.82 | |||||
3-1 Month Momentum % | 8.83 | |||||
6-1 Month Momentum % | -4.56 | |||||
12-1 Month Momentum % | -3.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.77 | |||||
Quick Ratio | 0.73 | |||||
Cash Ratio | 0.47 | |||||
Days Inventory | 207.5 | |||||
Days Sales Outstanding | 33.08 | |||||
Days Payable | 157.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.4 | |||||
Dividend Payout Ratio | 0.42 | |||||
3-Year Dividend Growth Rate | 58.7 | |||||
Forward Dividend Yield % | 0.4 | |||||
5-Year Yield-on-Cost % | 8.83 | |||||
Shareholder Yield % | 0.16 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 39.33 | |||||
Operating Margin % | 10.26 | |||||
Net Margin % | 8.24 | |||||
EBITDA Margin % | 12.54 | |||||
FCF Margin % | -0.82 | |||||
OCF Margin % | -0.67 | |||||
ROE % | 23.04 | |||||
ROA % | 10.98 | |||||
ROIC % | 27.79 | |||||
3-Year ROIIC % | 13.45 | |||||
ROC (Joel Greenblatt) % | 85.07 | |||||
ROCE % | 28.96 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 107.32 | |||||
PE Ratio without NRI | 105.08 | |||||
Shiller PE Ratio | 203.38 | |||||
PEG Ratio | 5.87 | |||||
PS Ratio | 8.84 | |||||
PB Ratio | 23.06 | |||||
Price-to-Tangible-Book | 23.06 | |||||
EV-to-EBIT | 77.09 | |||||
EV-to-EBITDA | 69.37 | |||||
EV-to-Revenue | 8.7 | |||||
EV-to-FCF | -1099.2 | |||||
Price-to-GF-Value | 0.74 | |||||
Price-to-Projected-FCF | 13.5 | |||||
Price-to-DCF (Earnings Based) | 4.41 | |||||
Price-to-Median-PS-Value | 0.96 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.13 | |||||
Price-to-Graham-Number | 10.38 | |||||
| Price-to-Net-Current-Asset-Value | 32.27 | |||||
Earnings Yield (Greenblatt) % | 1.3 | |||||
FCF Yield % | -0.09 | |||||
Forward Rate of Return (Yacktman) % | 18.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AstraZeneca Pharma India Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 22,755.8 | ||
| EPS (TTM) (₹) | 75.01 | ||
| Beta | 0.9964 | ||
| 3-Year Sharpe Ratio | 0.82 | ||
| 3-Year Sortino Ratio | 1.54 | ||
| Volatility % | 24.82 | ||
| 14-Day RSI | 35.82 | ||
| 14-Day ATR (₹) | 230.418908 | ||
| 20-Day SMA (₹) | 8452.425 | ||
| 12-1 Month Momentum % | -3.09 | ||
| 52-Week Range (₹) | 7551.5 - 9849.5 | ||
| Shares Outstanding (Mil) | 25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AstraZeneca Pharma India Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AstraZeneca Pharma India Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 32.000000 Cash Dividend | 2025-07-18 | 9,394.00 (+1.84%) | ||
| INR 24.000000 Cash Dividend | 2024-07-05 | 7,128.85 (+11.41%) |
Show
Entries
AstraZeneca Pharma India Ltd Frequently Asked Questions
What is AstraZeneca Pharma India Ltd(NSE:ASTRAZEN)'s stock price today?
The current price of NSE:ASTRAZEN is ₹8058.00. The 52 week high of NSE:ASTRAZEN is ₹9849.50 and 52 week low is ₹7551.50.
When is next earnings date of AstraZeneca Pharma India Ltd(NSE:ASTRAZEN)?
The next earnings date of AstraZeneca Pharma India Ltd(NSE:ASTRAZEN) is .
Does AstraZeneca Pharma India Ltd(NSE:ASTRAZEN) pay dividends? If so, how much?
The Dividend Yield %  of AstraZeneca Pharma India Ltd(NSE:ASTRAZEN) is 0.4% (As of Today), Highest Dividend Payout Ratio of AstraZeneca Pharma India Ltd(NSE:ASTRAZEN) was 0.42. The lowest was 0.04. And the median was 0.16. The  Forward Dividend Yield % of AstraZeneca Pharma India Ltd(NSE:ASTRAZEN) is 0.4%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on AstraZeneca Pharma India Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers